Source｜National Medical Security Bureau

Recently, the National Medical Insurance Bureau issued the "Response of the National Medical Insurance Bureau to Recommendation No. 4126 of the Fourth Session of the 13th National People's Congress" (medical insurance letter [2021] ] No. 28) (hereinafter referred to as "Reply").

The "Answer" clarified the direction of the next step on the basis of explaining the progress of centralized drug procurement.

The "Notice" pointed out that, in accordance with the decisions and deployments of the Party Central Committee and the State Council, the National Medical Insurance Bureau will work with relevant departments to promote the reform of the centralized drug procurement system in an orderly manner, and successfully carried out five batches of 218 drug centralized procurement.

At the same time, under the guidance and promotion of the National Medical Insurance Bureau, all the ** provinces across the country have carried out centralized drug procurement in the form of independent procurement or cross-provincial alliance procurement.

Concentrated procurement promises to give priority to the use of selected products and ensure the completion of the agreed procurement volume, giving companies stable market expectations, providing companies with a platform for fair competition in the sun, squeezing out the cost of intermediate circulation links, and competition among companies The focus of the original "rebate competition" to the competition of quality and price will help form a legal and market-oriented good business environment, and will also help increase industry concentration and promote high-quality development of the industry.

Regarding the proposal to allow Chinese patent medicines to enter the centralized drug procurement as soon as possible, and to allow more traditional Chinese medicine manufacturers to participate in the competition fairly, the "Notice" mentioned the "Opinions of the General Office of the State Council on Promoting the Normalization and Institutionalization of Centralized Drug Procurement Work" "(Guobanfa [2021] No. 2) clearly stated that "exploring the merger of different generic drugs with similar indications or functions and indications to carry out centralized and volume procurement" provides a basic follow for the centralized procurement of proprietary Chinese medicines.

At present, Qinghai Province, Jinhua in Zhejiang Province, Puyang in Henan Province and other places have carried out centralized procurement explorations for some Chinese patent medicines that are in high demand and high in value, and have achieved positive results.

In addition, the "Notice" also clearly pointed out that in the next step, the National Medical Insurance Bureau will work with relevant departments to improve the quality evaluation standards of Chinese patent medicines and formula granules, insist on quality first, oriented by clinical needs, and value-added Starting with the variety of products, scientifically and steadily promote the reform of centralized procurement of Chinese patent medicines and formula granules.

END